Compare Eos Energy Enterprises Inc (EOSE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Recursion Pharmaceuticals Inc — how do they compare? Eos Energy Enterprises Inc trades at $2.53 (market cap $1.01B), while Recursion Pharmaceuticals Inc trades at $4.34 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.1× Eos Energy Enterprises Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| EOSE | RXRX | |
|---|---|---|
Market Cap | $1.01B | $2.14B |
Volume | 39,626,541 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $19.19 | $6.79 |
52-Week Low | $2.77 | $2.84 |
Typical Hold Time | 16 Days | 23 Days |
Enterprise Value | $1.34B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.575, down 16.94% in the last session, reflecting ongoing volatility despite positive business developments. The company shows rapid revenue growth with $214M projected for 2026 but faces significant profitability challenges with a -246.76% net income margin. Recent catalysts include an $87M Department of Energy loan advance and a major partnership with Google for a $350M West Virginia energy project announced September 2, 2026.
While analyst consensus remains cautiously optimistic with a $7.10 price target representing 176% upside, the stock carries substantial risk due to persistent losses and high debt-to-asset ratio of 91.87%. The technical picture is bearish with weak momentum, though oversold RSI levels may indicate potential for near-term bounce. Investment appeal hinges on successful execution of production scaling and path to profitability.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
